单剂量诺华A、C、W-135和Y群脑膜炎球菌CRM-197结合疫苗（Menveo®）或Menactra®在健康青少年中免疫应答的持久性
Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.
作者信息
Gill Christopher J, Baxter Roger, Anemona Alessandra, Ciavarro Giuseppe, Dull Peter
机构信息
Novartis Vaccines and Diagnostics, Cambridge, MA, USA.
出版信息
Hum Vaccin. 2010 Nov;6(11):881-7. doi: 10.4161/hv.6.11.12849. Epub 2010 Nov 1.
Abstract
The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.
摘要
在接种一剂Menveo®（A、C、W-135、Y群脑膜炎球菌结合疫苗；诺华公司）或Menactra®（四价脑膜炎球菌多糖疫苗）（赛诺菲巴斯德公司）22个月后，评估了青少年人群中人类杀菌活性（hSBA）反应的持续性。对于A、W-135和Y血清群，接种A、C、W-135、Y群脑膜炎球菌结合疫苗的受试者中hSBA滴度≥8的比例显著高于接种四价脑膜炎球菌多糖疫苗的受试者。
相似文献
1
Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.单剂量诺华A、C、W-135和Y群脑膜炎球菌CRM-197结合疫苗（Menveo®）或Menactra®在健康青少年中免疫应答的持久性
Hum Vaccin. 2010 Nov;6(11):881-7. doi: 10.4161/hv.6.11.12849. Epub 2010 Nov 1.
2
Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.青少年接种四价脑膜炎球菌结合疫苗的抗体持久性和加强应答。
J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20.
3
Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.一种研究性四价脑膜炎球菌结合疫苗与已获许可的脑膜炎球菌ACWY结合疫苗在青少年中的III期比较。
Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.
4
Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.青少年脑膜炎球菌病四价结合疫苗加强免疫后抗体持久性和应答反应。
Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38.
5
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.成人四价脑膜炎球菌疫苗接种：研究用结合疫苗MenACWY-CRM与已获许可疫苗Menactra的III期比较。
Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.
6
Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.采用两种不同检测方法评估儿童接种 MenACWY-CRM 疫苗后的抗体持久性和加强免疫应答。
Vaccine. 2019 Jul 26;37(32):4460-4467. doi: 10.1016/j.vaccine.2019.06.076. Epub 2019 Jul 3.
7
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.一剂次脑膜炎球菌（A、C、W和Y群）多糖白喉类毒素结合疫苗的安全性和免疫原性
Vaccine. 2016 Oct 17;34(44):5273-5278. doi: 10.1016/j.vaccine.2016.09.003. Epub 2016 Sep 15.
8
Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.一种研究性A、C、W、Y群脑膜炎球菌结合疫苗（MenACWY-CRM）在2至75岁健康印度受试者中的安全性和免疫原性。
Int J Infect Dis. 2015 Sep;38:36-42. doi: 10.1016/j.ijid.2015.07.003. Epub 2015 Jul 9.
9
A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.两种实验性A群、C群、W群和Y群脑膜炎球菌疫苗制剂的比较评估：一项2期随机对照试验的结果
Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.
10
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.无佐剂四价脑膜炎球菌糖共轭疫苗在婴儿中的免疫原性和免疫记忆
Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.
引用本文的文献
1
Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.MenACYW-TT疫苗接种后抗体持久性建模及与其他四价脑膜炎球菌疫苗的比较分析
Sci Rep. 2025 Jul 10;15(1):24990. doi: 10.1038/s41598-025-08112-0.
2
Modeling protective meningococcal antibody responses and factors influencing antibody persistence following vaccination with MenAfriVac using machine learning.利用机器学习对MenAfriVac疫苗接种后的保护性脑膜炎球菌抗体反应及影响抗体持久性的因素进行建模。
PLoS One. 2025 May 14;20(5):e0323384. doi: 10.1371/journal.pone.0323384. eCollection 2025.
3
Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children.四价脑膜炎球菌结合疫苗（MenACYW-TT）的五年免疫持久性及儿童加强剂量的免疫原性和安全性
Infect Dis Ther. 2025 May;14(5):991-1010. doi: 10.1007/s40121-025-01121-6. Epub 2025 Apr 1.
4
Meningococcal Vaccination in the United States: Past, Present, And Future.美国的脑膜炎球菌疫苗接种：过去、现在与未来
Paediatr Drugs. 2025 May;27(3):331-349. doi: 10.1007/s40272-024-00666-2. Epub 2025 Feb 20.
5
Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines.基于单磷酰脂质 A 的佐剂增强多价脑膜炎球菌多糖结合疫苗的免疫原性。
Immunohorizons. 2024 Apr 1;8(4):317-325. doi: 10.4049/immunohorizons.2400013.
6
Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.中国 9 岁以下儿童接种脑膜炎球菌疫苗的成本效益分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2313872. doi: 10.1080/21645515.2024.2313872. Epub 2024 Feb 13.
7
Increasing the High Throughput of a Luminescence-Based Serum Bactericidal Assay (L-SBA).提高基于发光的血清杀菌试验（L-SBA）的高通量
BioTech (Basel). 2021 Sep 18;10(3):19. doi: 10.3390/biotech10030019.
8
[ (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy].[意大利引入四价结合疫苗进行抗脑膜炎球菌疫苗接种的（卫生技术评估）]
J Prev Med Hyg. 2021 May 13;62(1 Suppl 1):E1-E128. doi: 10.15167/2421-4248/jpmh2021.62.1s1. eCollection 2021 Mar.
9
Meningococcal disease and vaccination in college students.脑膜炎球菌病与大学生疫苗接种。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4675-4688. doi: 10.1080/21645515.2021.1973881. Epub 2021 Oct 6.
10
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.在接种脑膜炎球菌疾病疫苗 3 年前作为幼儿接种的儿童中，作为加强剂量接种的一种研究性四价脑膜炎球菌结合疫苗的免疫原性和安全性：一项 III 期、开放性、多中心研究。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-10. doi: 10.1080/21645515.2021.1902701. Epub 2021 Jun 4.
本文引用的文献
1
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.成人四价脑膜炎球菌疫苗接种：研究用结合疫苗MenACWY-CRM与已获许可疫苗Menactra的III期比较。
Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.
2
Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.免疫实践咨询委员会（ACIP）关于对长期存在脑膜炎球菌病风险增加的人群进行再次接种疫苗的最新建议。
MMWR Morb Mortal Wkly Rep. 2009 Sep 25;58(37):1042-3.
3
Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.补体介导的杀菌和调理活性在预防脑膜炎球菌病中的相对重要性。
Vaccine. 2009 Jun 24;27 Suppl 2(Suppl 2):B117-25. doi: 10.1016/j.vaccine.2009.04.066. Epub 2009 May 23.
4
Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.一种研究性四价脑膜炎球菌结合疫苗与已获许可的脑膜炎球菌ACWY结合疫苗在青少年中的III期比较。
Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.
5
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.杀菌性抗体是预防脑膜炎球菌病的免疫替代指标。
Vaccine. 2009 Jun 24;27 Suppl 2:B112-6. doi: 10.1016/j.vaccine.2009.04.065. Epub 2009 May 21.
6
Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.使用人血测量疫苗诱导的血清被动保护活性的脑膜炎球菌血症体外模型。
Clin Vaccine Immunol. 2009 Jun;16(6):785-91. doi: 10.1128/CVI.00007-09. Epub 2009 Apr 1.
7
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.2005年土耳其人群中C群脑膜炎球菌血清杀菌抗体活性以及A、C、W135和Y群特异性IgG浓度的年龄特异性血清阳性率。
Vaccine. 2007 Oct 10;25(41):7233-7. doi: 10.1016/j.vaccine.2007.07.019. Epub 2007 Aug 1.
8
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.流行性脑膜炎、脑膜炎球菌血症和脑膜炎奈瑟菌
Lancet. 2007 Jun 30;369(9580):2196-2210. doi: 10.1016/S0140-6736(07)61016-2.
9
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.英国脑膜炎球菌C结合疫苗接种失败的临床和免疫风险因素
J Infect Dis. 2006 Dec 15;194(12):1745-52. doi: 10.1086/509619. Epub 2006 Nov 8.
10
Meningococcal surrogates of protection--serum bactericidal antibody activity.保护的脑膜炎球菌替代指标——血清杀菌抗体活性
Vaccine. 2005 Mar 18;23(17-18):2222-7. doi: 10.1016/j.vaccine.2005.01.051.
Zotero 插件